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Abstract Otitis media with effusion is one of the most common diseases in children. Its treatment remains
controversial. Clinical practice guidelines of OME allow watchful waiting for 3 months before treatment if the child
with OME is not at risk for speech/language/or learning problems. Tympanostomy tube insertion is the preferred
initial procedure when a child becomes a surgical candidate. Complementary or alternative medicine is not
recommended as a treatment for OME. This paper provides a systematic review of management of OME, which we
hope will be helpful for clinicians.
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Abbreviations
OME otitis media with effusion
AOM acute otitis media
COME chronic otitis media with effusion
SOM secretory otitis media
MEE middle ear effusion
L-NAME N (G)-nitro-L-arginine methyl ester
A85783 a platelet activating factor antagonist
sTNERI tumor necrosis factor soluble receptor type I
HL hearing loss
MVTI miringotomy ventilation tube insertion
ET eustachian tube
HRQoL health-related quality of life
FHS functional heath status
RAOM recurrent acute otitis media
LM laser miringotomy
LTMF Laser-assited tympanic membrane fenestration
Otitis media with effusion（OME）is one of the most
common diseases in childhood. In the first year of life, >
50% of children will experience OME, increasing to
60% by 2 years, with another peak at age of 6 years. It is
a leading cause of conductive hearing loss in children.
However, its treatment remains controversial. This paper
presents a systematic review of the treatments that may
be beneficial for the clinicals. —（Clinicians） 1
Non-surgical managements
1.1 The“wait and see”approach
Spontaneous improvement of secretory otitis media
（SOM）is common. Type B tympanometry improves in
78% to 88% of ears［1］. OME after untreated acute otitis
media（AOM）resolves in 59% of the cases by 1 month
（95% CI: 50-68%）. OME of unknown duration resolves
spontaneously in 28% of the cases by 3 months（95%
CI: 68-80%）, and in 42% by 6 months（95% CI:
35-49%）［2］. Renko et al showed similar results in a pro⁃
spective study［3］, in which the mean duration of OME
was 10.2 days（rang: 1-58 days）. A mere 10 out of 90
cases continued to have OME after 29-43 days. Be⁃
cause the natural history of OME is favorable and most
interventions（medicine or surgery）may carry adverse
effects or sequelae, a 3-month period of observation is
recommended before treatment for a child who is not at
risk for speech/language/ or learning problems ［4］. This
3-month period of watchful waiting may include interval
visits at which OME is monitored using pneumatic otos⁃
copy , tympanometry or both. In contrast, chronic OME
had only a 26% resolution rate by 6 months and 33% by
1 year［1］. There is only marginal benefit for longer obser⁃
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vation. Interventions are therefore recommended for
chronic OME.
1.2 Antibiotics
Although OME is acknowledged as a sterile disease,
studies show that the middle ear effusion from children
with OME contains bacteria. Bluestone et al［5］ analyzed
bacterioligic data from 37 studies of AOM and OME con⁃
ducted at the Otitis Media Research Center at Children’
s Hospital of Pittsburgh from 1980-1989. In these stud⁃
ies, 7,396 aspirates were obtained from 5,099 patients.
Some 4,589 aspirates were from patients in 10 studies
involving children with OME who underwent tympanos⁃
tomy tube insertion. Haemopbilus influenzae was the
most common organism found in OME aspirates at 15%
（23% in AOM）, followed by Moraxella catarrbalis at
10%（14% in AOM）. Streptococcus pneumoniae was
found in 7% of aspirates from children with OME and
35% of aspirates from children with AOM. During the
10 years of the study, an increase in β-lactamase pro⁃
ducing organisms, both H.influenzae and M.catarrbalis,
was noted. At the same time, cultures of chronic MEE
from Japan and Finland also showed H.influenzae to be
the most common pathogen isolated（20.2% and 8%）,
followed by S.pneumoniae（10.6% and 4.3%）, and M.
catarrbalis（2.3% and 3.5%）［6］. Rayner et al［7］ collected
a total 93 effusion specimens from pediatric outpatients
seen for myringotomy and tube placement for chronic（>
3 months） OME（median age: 17 months）. Eleven
（11.8%）of the 93 specimens was tested positive by cul⁃
ture, PCR, and RT-PCR for H influenzae. Twenty nine
specimens were positive by RT-PCR for H influen⁃
zae-specific mRNA. These bacteria may constitute a
fundamental factor in the etiology, prognosis and treat⁃
ment. From their studies on OME, Mandel et al［8］ con⁃
cluded that antibiotics might be useful in selected pa⁃
tients, particularly those with chronic OME（3 months or
longer of bilateral effusion or 6 months or longer of uni⁃
lateral effusion）for whom surgery was being considered.
A one-time short course of antibiotic might allow cancel⁃
lation or at least postponement of a surgical procedure.
This is particularly beneficial in spring/summer time
when one would like to avoid placing tubes in the ears
and placing the child at risk for otorrhea due to water ex⁃
posure. However, the long-term efficacy is not sure and
unnecessary use of antibiotic increases bacteria resis⁃
tance to these drugs. Antibiotics efficient against sensi⁃
tive bacteria can result in improvement of OME. Culture
and sensitive test before antibiotic use are therefore rec⁃
ommended.
1.3 Steroids
Steroids are used commonly in clinical managements
of OME, either systemic or topical（instillation of ste⁃
roids in the middle ear）. It is hypothesized that steroids
may clear effusion by (1) stabilizing membrane phospho⁃
lipid breakdown thus preventing formation of arachidon⁃
ic acid and associated inflammatory mediators; (2)
shrinking peritubal lymphoid tissue; (3) enhancing secre⁃
tion of Eustachian tube surfactant; and (4) reducing mid⁃
dle ear fluid viscosity［9］. Christopher et al［10］designed
a systematic review to examine evidence for or against
treating OME with systemic or topical nasal steroids.
The odds ratio for persisting OME after short-term fol⁃
low-up was 0.22（95% confidence interval: 0.08-0.63）
in children treated with oral steroids as compared with a
control and 0.32（95% confidence interval: 0.20-0.52）
in children treated with oral steroids plus an antibiotic
as compared with antibiotic treatment only. They con⁃
cluded that steroids alone or in combination with an anti⁃
biotic led to accelerated OME resolution in short-term.
However, there is no evidence to support long-term ben⁃
efit from treating hearing loss associated with OME with
either oral or topical nasal steroids. These treatments
are not recommended at the present time. Dhooge et al
［11］and Butler et al［12］made the same conclusions. Butler
et al emphasized documentation of pre-treatment hear⁃
ing loss, longer follow-ups and ideally incusion of
health-related quality of life and hearing assessments in
future studies. Further studies are needed for convincing
evidence for steroid treatment for OME.
1.4 Antihistamines and/or decongestants
Histamine, found in middle ear effusion, is a potent
pharmacological mediator released at an early stage of
allergic reaction or general inflammatory process, which
increases permeability of small blood vessels. In addi⁃
tion, histamine can cause mucociliary dysfunction in the
tubotympanum area, resulting in middle ear effusion
since cilia have a significant role in eliminating middle
ear effusions［13］. Theoretically, antihistamines may help
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reduce histamine-related allergic elements and decon⁃
gestants may result in mucosal shrinkage and improve⁃
ment of Eustachian tube patency. Antihistamines and
decongestants are popular interventions for OME to“dry
up the fluid”and“open the Eustachian”. Witmer et al
concluded that pharmacologic treatment had significant
effect in its resolving OME when compared to no treat⁃
ment（P=0.0017）, although the effect size was weak（R=
0.07）［14］. In contrast, a Cochrane review by Griffin GH
et al［15］ showed that those treated with antihistamines
and/or decongestants experienced 11% more side effects
than those who recived no treatment. No statistical or
clinical benefit was found for any of the interventions
studied. Because the pooled data demonstrated no bene⁃
fit but possible harm from use of antihistamines or de⁃
congestants, alone or in combination with other manage⁃
ment measures in OME, they recommended against their
use. Other studies［16, 17］ have also failed to demonstrate
any practical impact of these drugs in SOM. Clinical
practice guidelines reflect this opinion on the use of anti⁃
histamines and/or decongestants［4］. Adverse effects from
using these drugs include insomnia, hyperactivity,
drowsiness, behavioral change, and bloodpressure vari⁃
ability. At present, although many clinicians still use the
antihistamine/decongestants to delay surgery, they
should be advised against.
1.5 Surfactant
In the year of 1963, Flisberg et al pointed out that
there was a substance in the Eustachian tube that could
reduce the surface-tension［18］. Studies show more sphin⁃
gomyelin and less phosphatidylcholine in the Eusta⁃
chian tube and nose than in the lung, while phosphati⁃
dylethanolamine has the same distribution in both places
［19］. Surfactant-producing epithelium in the ET is simi⁃
lar to type II pneumocytes［20］. The phosphatidylcholine/
sphigomyrlin ratio is significantly lower in Eustachian
tube mucus from children with secretory otitis media
than otologically healthy children ［19］, indicating that
change of surfactant may be a cause of OME. Normal Eu⁃
stachian tube fuctioning depends on several mechanical
properties, including the ET opening pressure（P open）,
compliance（ETC）and hysteresis (η). Surfactant plays
an important role in regulating the functions of ET. In a
gerbil model, exogenous surfactant resulted in a dramat⁃
ic decrease in Eustachian tube opening pressure in both
normal ears and those with effusion ［21］. Samir
et al［22］ came to the same conclusion in their study,
where removal of the normal mucosa did not significant⁃
ly alter Popen but resulted in a decrease in ETC and η
（P<0.05）. Treatment of the mucosa with Infasurf was ef⁃
fective in reducing Popen and restoring both ETC and η
to baseline values（P< 0.05）. This may indicate that in⁃
creasing surfactant in the Eustachian tube is beneficial
in reducing persistent OME.
1.6 Vaccines
OME may be the continuum of AOM and acquisition
of viruses and bacteria in the nasopharynx is considered
to be the first essential step in the pathogenesis of OME.
Vaccination against these pathogens for children prone
to OME or AOM may be effective in preventing addition⁃
al recurrences. In a randomised controlled double-blin
trial to explore the effect of a pneumococcal conjugate
vaccine in reducing the risk of OME, Straetemans et al
［23］ concluded that vaccination appeared to reduce the
point prevalence of OME in children without older sib⁃
lings. This effect was not apparent in children with older
siblings. Ozgur SK et al［24］ also showed that influenza
vaccine was effective in reducing AOM and OME epi⁃
sodes in 6 to 60-month-old day care children, especial⁃
ly during the influenza season. However, in the trail by
Van Heerbeek et al［25］, the overall recurrence rate of bi⁃
lateral OME was 50%. Combined pneumococcal conju⁃
gate and polysaccharide vaccination did not prevent re⁃
currence of OME among children 2 to 8 years of age pre⁃
viously known to have persistent OME. Therefore, they
concluded that pneumococcal vaccines were not indicat⁃
ed for treatment of children suffering from recurrent
OME. Similarly, according to Brouwer et al［26］, pneumo⁃
coccal vaccination has no beneficial effect compared
with control vaccination against HRQoL or FHS in chil⁃
dren 1 to 7 years old with RAOM. Additional studies are
apparently needed to address these controversial opin⁃
ions.
1.7 Cytokine Inhibitors
Cytokines play an important role as initiators, media⁃
tors and regulators of middle ear inflammation and sub⁃
sequent molecular-pathological processes in middle ear
tissues, leading to histopathological changes in the mid⁃
··70
Journal of Otology 2008 Vol. 3 No. 2
dle ear cavity. The existence of high concentration of
pro-inflammatory（TNFα, TNFβ, IL1β, IFNγ, IL-6 and
IL-8）, immunoregulatory（IL-2 and IL-10）and allergic
cytokines（IL-4 and IL-5） in the middle ear effusion
support the hypothesis that the cytokines can contribute
to the conversion of a inflammatory process to a chronic
state［27］. The imbalance in the ratio of pro-inflammatory
cytokines and inhibitors may lead to the inflammatory
process in COME［28］. After inoculation with recombinant
Il-1—IL-1beta, middle ear effusion through the ear⁃
drum has been found to be similar with injection of endo⁃
toxin. Anti-IL-1 receptor antibodies inhibit the patho⁃
logical changes induced by the endotoxin［29］. In a study
by Kim et al［30］, the L-NAME, A85783 and sTNFRI
groups showed significantly reduced capillary permeabil⁃
ity, subepithelial edema and inflammatory cell infiltra⁃
tion in comparison with the group treated with LPS.
They concluded that the L-NAME, A85783, and sTN⁃
FRI could be alternative treatments for OME. However,
similar effect has yet to be shown in human. It is hoped
that cytokine inhibitors will have a role in treatment of
OME in human in the future.
1.8 Other medical treatments
Other medical treatments are also used in manage⁃
ment of OME. Mucolytics, for example, have a dispers⁃
ing action on the excessively viscous mucus in the Eu⁃
stachian tube. The herbal medicine sirei-to is also used
in the treatment of OME to resolve the inflammation and
immune response associated with SOM. Their effects
need to be evaluated in future studies.
1.9 Inflation
Because of the low cost and absence of adverse ef⁃
fects it is reasonable to consider autoinflation whilst
awaiting natural resolution of OME. The efficacy of infla⁃
tion is highly dependent on the timing and frequency of
the treatment. In a randomized study by Stangerup et al
［31］, after 2 weeks of autoinflation, tympanometric param⁃
eters improved in 64% of the ears, remained unchanged
in 34% , and deteriorated in the remaining 2% , com⁃
pared with control group in which tympanometric find⁃
ings improved in 15% of ears, remained the same in
71%, and deteriorated in the remaining 14%. Lesinskas
［32］got similar results, e.g., middle ear inflation and mid⁃
dle ear inflation plus antibiotics resulted in better treat⁃
ment outcomes than observation alone. They concluded
that daily middle ear inflation was effective for SOM in
adult patients. Alper et al［33］, however, documented dis⁃
placement of fluid by inflation from the tympanum to the
mastoid and petrous air cells on MRI imaging. This fluid
redistribution could result in a false impression of im⁃
provement when evaluated using conventional clinical
methodologies such as tympanometry and otoscopy.
They suggested that repeated air inflation could prevent
development of OME in 50% of ears with functional Eu⁃
stachian tube obstruction. Future research should ad⁃
dress the accuracy of treatment outcome evaluations and
long-term impact of inflation on developmental changes
in children with OME.
2 Surgical treatment
2.1 Tympanocentesis and medicine injection into the
middle ear
Tympanocentesis in the early stage of OME can re⁃
store hearing and tympanic membrane mobility in the
majority of patients. Injection of medicines（e.g., ste⁃
roids, batroxobin, and ambroxol）following aspiration of
fluid within the middle ear can be beneficial. Studies
have shown that intratympanically injected batroxobin
produced better treatment outcomes than the controls in
OME［34-37］. However, these studies have involved small
size samples and have not reported long-term effects .
We expect that more investigations into these treatments
will take place in the future.
2.2 Tympanostomy
Tympanostomy is performed in case of highly viscous
fluid in the middle ear that is difficult to aspirate to facil⁃
itate fluid elimination and improve hearing. At present,
tympanostomy is rarely performed alone but is often fol⁃
lowed by insertion of tympanostomy tubes. Mandel et al
［38］ showed that mringotomy alone offered no advantage
over no surgery in terms of duration of middle-ear effu⁃
sion, number of AOM episodes, and number of subse⁃
quent surgical procedures.
2.3 Ventilation Tubes
Tympanostomy tube insertion is the most frequently
performed operation in children with OME all over the
world, but whether it is free of complications is still be⁃
ing debated. Vlastarakos et al［39］ found that complica⁃
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tions associated with tympanostomy tube insertion were
more frequent than anticipated, reaching 80% of operat⁃
ed ears under specific circumstances and in certain sub⁃
groups of children. The main complications were puru⁃
lent otorrhea（10-26%）myringosclerosis（39-65%）seg⁃
mental atrophy（16-75%）atrophic scars and pars flacci⁃
da retraction pockets（21-28%） tympanic membrane
perforation（3%, but as high as 24% with T-tubes）cho⁃
lesteatoma（1%）and granulation tissue（5-40%）. Fur⁃
thermore in a study to determine the cost/effectiveness
of ventilation tube in comparison with watchful waiting
in children with persistent OME Hartman et al［40］ found
no differences in language development. Given the asso⁃
ciated with ventilation tube treatment, it was not recom⁃
mended as a standard treatment in young children with
persistent OME identified in population-based screen⁃
ing. Rovers et al［41］and Paradise et al［42］agreed with this
conclusion. They indicated that grommets might be used
in young children who grew up in an environment with a
high infection load, in older children with bilateral hear⁃
ing levels of 25 dB HL or greater for at least 12 weeks,
or in children with bilateral effusion for at least 6 addi⁃
tional months and in children with unilateral effusion for
at least 9 additional months. To avoid the complications
associated with tympanostomy tube insertion and bal⁃
ance cost/effectiveness, the ventilation tube insertion
should be performed only in selected patients with ap⁃
propriate indications.
2.5 Adenoidectomy
The adenoid may play an important role in the patho⁃
genesis of OME. Adenoid hypertrophy can cause me⁃
chanical obstruction of the Eustachian tube. The ade⁃
noid can also be the source of bacteria infection which
can induce inflammation of the middle ear. Petri et al［43］
have suggested that the adenoid may provide a microen⁃
vironment for the generation of CD4+, CD45RO+, L-se⁃
lectin-, CXCR4 + and CCR5 + T lymphocytes（a lympho⁃
cyte phenotype found in the middle ear effusion）. When
chronic adenoid infection is suspected, adenoidectomy
may be beneficial in treating otitis media in children
who are older than 4 years of age and who have previous⁃
ly undergone tympanostomy-tube insertion［44］. From a
study of 50,000 children over a 24 year period［45］, ade⁃
noid surgery at the time of MVTI is associated with re⁃
duced odds of subsequent MVTI procedure in children
with or with out adenoid/tonsil disease with no differenc⁃
es in the length of hospital stay between MVTI alone
and MVTI with adenoidectomy. Therefore, the low com⁃
plication rates with adenoidectomy and short hospital
stays made adjunctive adenoidectomy a potentially
cost-effective first line management option for OME.
2.6 Laser myringotomy
Laser myringotomy is an easy and quick procedure
that can be performed in the medical office under topi⁃
cal anesthesia and is suitable for patients with AOM or
for those who need short-term ventilation for SOM. The
effect of the treatment is dependent on the duration of
tympanum perforation. Factors that affect the duration of
patency of tympanic membrane include (1) The spot
size: Deutsch et al［46］approved that spot sizes of 2.4 and
2.6 mm carried a higher rate of patency than 2.0-mm
spot size at 3 weeks following LTMF. (2) The position of
perforation: laser mringotomy in the anterior and inferior
areas lasted longer than posterior LM［46］. And (3) The ag⁃
es: from Cohen et al［47］, perforation lasted a mean 22
days in adults, 17days in children, and 11 days in in⁃
fants. In a long-term follow-up study, E Hassmann con⁃
cluded that the use of CO2 laser for myringotomy has no
negative effect on the function of the cochlea and the
healing of the tympanic membrane after myringotomy
was uneventful with a low percentage of permanent se⁃
quelae［48］. It can be used in the place of ventilation tube
in treatment of OME.
2.7 Retrograde catheterization via the Eustachian tube
Along with the increasing use of nasal endoscope, ret⁃
rograde catheterization via the Eustachian tube becom⁃
ing a new treatment option for OME. A catheter is insert⁃
ed into the tympanum through the Eustachian tube to
clear the middle ear secretion, inject medicines for mid⁃
dle ear mucosa recovery, and balance the pressure in
the tympanum. Studies in China［49, 50, 51］ have shown that
Eustachian tube catheterization is a safe, easy and effec⁃
tive treatment for secretory otitis media. However, some
scholars have indicated that Eustachian catheterization
is not in physiological for the ET and may cause damage
to it. They［52］ suggest the long-term effects of the treat⁃
ment should be investigated before it is used frequently.
2.8 Mastoid and middle ear surgery
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The indications for mastoid and middle ear surgeries
are: 1) recurrent OME after exhausting other manage⁃
ment strategies such as tympanocentersis, and ventila⁃
tion tube insertion; 2) large quantity of fluid in the mas⁃
toid air cells on radiography; and 3) progressive develop⁃
ment of cholesterol granuloma in the middle ear. Al⁃
though mastoid and middle ear surgeries have the poten⁃
tial of complete elimination of diseased tissues, restora⁃
tion of ventilation function of the tympanic sinus and
mastoid air cells, as well as prevention of recurrence,
they should be performed only when CSOM fails to re⁃
spond to other treatments［53］.
As we know, treatment of OME remains controversial
and OME remains the most common disease leading to
hearing loss which can impair cognitive language
speech and psychosocial development in affected chil⁃
dren. Our review of pharmacological treatments, mringot⁃
omy and ventilation tube insertion for OME shows no sig⁃
nificant difference between drug treatments and mringot⁃
omy, but distinct benefits with ventilation tube insertion
than the other two. We recommend that surgical inser⁃
tion of ventilation tube should be considered in a child
with OME who is at risk for speech/language/hearing
loss/ or learning problems to prevent these problems
from occurring. Drug treatments or mringotomy is not
recommended because of their unsubstantiated benefits.
Other surgical treatments need to be further studies for
their long-term effects. It is hoped that continued re⁃
search efforts will improve treatment outcomes for pa⁃
tients with OME.
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Group
High Dose
Low Dose
Yu Quan Wan
Control
Number
10
12
11
10
before
after
before
after
before
after
before
after
GLU（mm01/L）
28.89±0.86
21.86 ±1.45**##
28.60±0.95
23.28±1.25*##
28.85±1.02
22.62±1.18*#
28.76±1.05
28.60±1.69
TG (mm01/L)
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0.09±0.04**##
0.29±0.02
0.15±0.07**##
0.35±0.01
0.34±0.08**#
0.32±0.07
0.32±0.04
Table 5 Glucose(GLU) and triglyceride changes (TG)（mean ± SD）
*P＜0.05, **P＜0.01, compared to pretreatment levels. #P＜0.05, ##P＜0.01, compared to the control.
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